Study summary

Adding chemotherapy to osimertinib helped people live about 10 months longer

FLAURA2 trial (osimertinib plus chemo) · 557 people, phase 3 · Published January 2026, New England Journal of Medicine

47.5months median survival, vs 37.6 with osimertinib alone

What was tested

Osimertinib plus pemetrexed and platinum chemotherapy against osimertinib alone, as first treatment for advanced lung cancer with a common EGFR mutation (exon 19 deletion or L858R).

What they found

What it means

Gives people a choice between a stronger start with more side effects, or osimertinib pills alone.

N Engl J Med, via PubMed ↗ Trial record NCT04035486 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.